Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr;12(Suppl 1):S206-S213.
doi: 10.21037/jgo-20-133.

Systemic therapy in addition to cytoreduction and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: recent insights from clinical studies and translational research

Checca Bakkers  1 , Geert A A M Simkens  1 , Ignace H J T De Hingh  1   2
Affiliations
Review

Systemic therapy in addition to cytoreduction and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: recent insights from clinical studies and translational research

Checca Bakkers et al. J Gastrointest Oncol. 2021 Apr.

Abstract

There is a lack of randomized or high-quality intention-to-treat cohort studies addressing the role of systemic therapy in addition to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) as part of the treatment of colorectal peritoneal metastases (PM). Therefore, the choice whether or not to treat patients with systemic therapy is currently mainly based on expert opinion. As a result, treatment with neoadjuvant and/or adjuvant systemic therapy is implemented in various ways around the world. The aim of this review was to provide an overview of recent insights with regard to the systemic treatment of PM of colorectal origin obtained from clinical studies and translational research.

Keywords: Systemic therapy; colorectal cancer; cytoreductive surgery (CRS); hyperthermic intraperitoneal chemotherapy (HIPEC); peritoneal metastases (PM).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/jgo-20-133). The focused issue was sponsored by the Peritoneal Surface Oncology Group International (PSOGI). IHJTDH reports a unrestricted grant was paid to the institute by RanD Biotech and QP&S. The authors have no other conflicts of interest to declare.

Comment in

References

    1. Lemmens VE, Klaver YL, Verwaal VJ, et al. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: A population-based study. Int J Cancer 2011;128:2717-25. 10.1002/ijc.25596 - DOI - PubMed
    1. Klaver YLB, Lemmens VEPP, Nienhuijs SW, et al. Peritoneal carcinomatosis of colorectal origin: Incidence, prognosis and treatment options. World Journal of Gastroenterology 2012;18:5489-94. 10.3748/wjg.v18.i39.5489 - DOI - PMC - PubMed
    1. Segelman J, Granath F, Holm T, et al. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg 2012;99:699-705. 10.1002/bjs.8679 - DOI - PubMed
    1. Kerscher AG, Chua TC, Gasser M, et al. Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: A longitudinal experience of 2406 patients over two decades. Br J Cancer 2013;108:1432-9. 10.1038/bjc.2013.82 - DOI - PMC - PubMed
    1. Segelman J, Akre O, Gustafsson UO, et al. Individualized prediction of risk of metachronous peritoneal carcinomatosis from colorectal cancer. Colorectal Dis 2014;16:359-67. 10.1111/codi.12552 - DOI - PubMed